Fecal biomarkers in inflammatory bowel disease. Issue 3 (March 2017) - Lopez, Robert N
Abstract: Over the last two decades, knowledge on fecal biomarkers has substantially increased. Nowadays, these non‐invasive markers of inflammation have significant clinical utility in the management of inflammatory bowel disease. Their use informs the decision to perform endoscopy before diagnosis is made right through to influencing therapeutic choices and the need for interval endoscopic assessment. In this review, the roles of two S100 proteins, calprotectin, and S100A12 are described along with that of lactoferrin, in the context of inflammatory bowel disease.